肌萎缩侧索硬化发病机制的研究进展

doi:10.3969/j.issn.1006-9771.2017.06.014

《中国康复理论与实践》 ›› 2017, Vol. 23 ›› Issue (6): 685-689.doi: 10.3969/j.issn.1006-9771.2017.06.014

肌萎缩侧索硬化发病机制的研究进展

郭永强^1,2, 李森¹, 张海鸿², 伍亚民¹

1.第三军医大学大坪医院野战外科研究所三室,创伤、烧伤与复合伤国家重点实验室,重庆市400042;
2.兰州大学第二医院骨科,甘肃兰州市 730030。

收稿日期:2017-01-13 修回日期:2017-02-13 出版日期:2017-06-25 发布日期:2017-06-27
通讯作者: 伍亚民,男,博士,博士研究生导师,主要研究方向：脊柱脊髓损伤。E-mail: yaminwu65@hotmail.com。
作者简介:郭永强(1990-),男,汉族,甘肃岷县人,硕士研究生,主要研究方向：脊柱脊髓损伤。

Advance in Pathogenesis of Amyotrophic Lateral Sclerosis (review)

GUO Yong-qiang^1,2, LI Sen¹, ZHANG Hai-hong², WU Ya-min¹

1. State Key Laboratory of Trauma, Burns and Combined Injury, the Third Department of Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing 400042, China;
2. Department of Orthopedics, Second Clinical Medical College of Lanzhou University, Lanzhou, Gansu 730030, China

Received:2017-01-13 Revised:2017-02-13 Published:2017-06-25 Online:2017-06-27
Contact: Correspondence to WU Ya-min. E-mail: yaminwu65@hotmail.com

摘要/Abstract

摘要： 肌萎缩侧索硬化(ALS)是最常见的一种运动神经元疾病,分为家族性和散发性。一般认为,ALS的发病机制主要包括基因突变、氧化应激、兴奋毒性、线粒体异常和免疫炎症反应等。这些发病机制之间相互联系,相互影响,最终引起了以运动神经系统为主的多系统病变。

关键词: 肌萎缩侧索硬化, 发病机制, 基因突变, 氧化应激, 兴奋毒性, 线粒体异常, 免疫炎症反应, 综述

Abstract: Amyotrophic lateral sclerosis (ALS), including the familial and the sporadic, accounts for the most proportion of motor neuron disease. The pathogenesis of ALS covers gene mutation, oxidative stress, excitotoxicity, mitochondrial dysfunction, immune and inflammatory, and so on. With interplay and interrelation, these mechanisms, finally, caused multisystem lesion especially motor neural system.

Key words: amyotrophic lateral sclerosis, pathogenesis mechanism, gene mutation, oxidative stress, excitotoxicity, mitochondrial dysfunction, immune and inflammatory, review

中图分类号:

R746.4

郭永强, 李森, 张海鸿, 伍亚民. 肌萎缩侧索硬化发病机制的研究进展[J]. 《中国康复理论与实践》, 2017, 23(6): 685-689.

GUO Yong-qiang, LI Sen, ZHANG Hai-hong, WU Ya-min. Advance in Pathogenesis of Amyotrophic Lateral Sclerosis (review)[J]. 《Chinese Journal of Rehabilitation Theory and Practice》, 2017, 23(6): 685-689.

参考文献

[1] Zarei S, Carr K, Reiley L, et al. A comprehensive review of amyotrophic lateral sclerosis [J]. Surg Neurol Int, 2015, 6(1): 171.
[2] Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis [J]. Lancet, 2011, 377(9769): 942-955.
[3] Swinnen B, Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis [J]. Nat Rev Neurol, 2014, 10(11): 661-670.
[4] Couthouis J, Raphael AR, Daneshjou R, et al. Targeted exon capture and sequencing in sporadic amyotrophic lateral sclerosis [J]. PLoS Genet, 2014, 10(10): e1004704.
[5] Maruyama H, Morino H, Kawakami H. [Causative genes for amyotrophic lateral sclerosis] [J]. [in Japanese]. Brain Nerve, 2016, 68(9): 1081-1086.
[6] Trias E, Ibarburu S, Barreto-Núñez R, et al. Significance of aberrant glial cell phenotypes in pathophysiology of amyotrophic lateral sclerosis [J]. Neurosci Lett, 2016, 636: 27-31.
[7] Ayers JI, McMahon B, Gill S, et al. Relationship between mutant SOD1 maturation and inclusion formation in cell models [J]. J Neurochem, 2017, 140(1): 140-150.
[8] Prudencio M, Hart PJ, Borchelt DR, et al. Variation in aggregation propensities among ALS-associated variants of SOD1: correlation to human disease [J]. Hum Mol Genet, 2009, 18(17): 3217-3226.
[9] Chattopadhyay M, Nwadibia E, Strong CD, et al. The disulfide bond, but not zinc or dimerization, controls initiation and seeded growth in amyotrophic lateral sclerosis-linked Cu, Zn superoxide dismutase (SOD1) fibrillation [J]. J Biol Chem, 2015, 290(51): 30624-30636.
[10] Ayers JI, Fromholt SE, O'Neal VM, et al. Prion-like propagation of mutant SOD1 misfolding and motor neuron disease spread along neuroanatomical pathways [J]. Acta Neuropathol, 2016, 131(1): 103-114.
[11] Bruijn LI, Miller TM, Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in ALS [J]. Annu Rev Neurosci, 2004, 27: 723-749.
[12] Wang I, Wu LS, Chang HY, et al. TDP-43, the signature protein of FTLD-U, is a neuronal activity-responsive factor [J]. J Neurochem, 2008, 105(3): 797-806.
[13] Gendron TF, Rademakers R, Petrucelli L. TARDBP mutation analysis in TDP-43 proteinopathies and deciphering the toxicity of mutant TDP-43 [J]. J Alzheimers Dis, 2013, 33(s1): S35-S45.
[14] Lu Y, Tang C, Zhu L, et al. The overexpression of TDP-43 protein in the neuron and oligodendrocyte cells causes the progressive motor neuron degeneration in the SOD1 G93A transgenic mouse model of amyotrophic lateral sclerosis [J]. Int J Biol Sci, 2016, 12(9): 1140-1149.
[15] Maruyama H, Kawakami H. Optineurin and amyotrophic lateral sclerosis [J]. Geriatr Gerontol Int, 2013, 13(3): 528-532.
[16] Patai R, Nógrádi B, Engelhardt JI, et al. Calcium in the pathomechanism of amyotrophic lateral sclerosis-Taking center stage? [J]. Biochem Biophys Res Commun, 2017, 483(4): 1031-1039.
[17] D'Amico E, Factor-Litvak P, Santella RM, et al. Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis [J]. Free Radical Bio Med, 2013, 65: 509-527.
[18] Barber SC, Shaw PJ. Oxidative stress in ALS: key role in motor neuron injury and therapeutic target [J]. Free Radical Biol Med, 2010, 48(5): 629-641.
[19] DeCoteau W, Heckman KL, Estevez AY, et al. Cerium oxide nanoparticles with antioxidant properties ameliorate strength and prolong life in mouse model of amyotrophic lateral sclerosis [J]. Nanomedicine, 2016, 12(8): 2311-2320.
[20] Melachroinou K, Xilouri M, Emmanouilidou E, et al. Deregulation of calcium homeostasis mediates secreted α-synuclein-induced neurotoxicity [J]. Neurobiol Aging, 2013, 34(12): 2853-2865.
[21] Kiselyov K, Muallem S. ROS and intracellular ion channels [J]. Cell Calcium, 2016, 60(2): 108-114.
[22] Wuolikainen A, Moritz T, Marklund SL, et al. Disease-related changes in the cerebrospinal fluid metabolome in amyotrophic lateral sclerosis detected by GC/TOFMS [J]. PLoS One, 2011, 6(4): e17947.
[23] Bonifacino T, Musazzi L, Milanese M, et al. Altered mechanisms underlying the abnormal glutamate release in amyotrophic lateral sclerosis at a pre-symptomatic stage of the disease [J]. Neurobiol Dis, 2016, 95: 122-133.
[24] Milanese M, Zappettini S, Onofri F, et al. Abnormal exocytotic release of glutamate in a mouse model of amyotrophic lateral sclerosis [J]. J Neurochem, 2011, 116(6): 1028-1042.
[25] Tani H, Dulla CG, Farzampour Z, et al. A local glutamate-glutamine cycle sustains synaptic excitatory transmitter release [J]. Neuron, 2014, 81(4): 888-900.
[26] Vucic S, Rothstein JD, Kiernan MC. Advances in treating amyotrophic lateral sclerosis: insights from pathophysiological studies [J]. Trends Neurosci, 2014, 37(8): 433-442.
[27] Rueda CB, Llorente-Folch I, Traba J, et al. Glutamate excitotoxicity and Ca 2+ -regulation of respiration: Role of the Ca 2+ activated mitochondrial transporters (CaMCs) [J]. Biochim Biophys Acta, 2016, 1857(8): 1158-1166.
[28] Magrané J, Cortez C, Gan WB, et al. Abnormal mitochondrial transport and morphology are common pathological denominators in SOD1 and TDP43 ALS mouse models [J]. Hum Mol Genet, 2014, 23(6): 1413-1424.
[29] Salehi M, Nikkhah M, Ghasemi A, et al. Mitochondrial membrane disruption by aggregation products of ALS-causing superoxide dismutase-1 mutants [J]. Int J Biol Macromol, 2015, 75: 290-297.
[30] Israelson A, Arbel N, Da Cruz S, et al. Misfolded mutant SOD1 directly inhibits VDAC1 conductance in a mouse model of inherited ALS [J]. Neuron, 2010, 67(4): 575-587.
[31] Sasaki S, Iwata M. Mitochondrial alterations in the spinal cord of patients with sporadic amyotrophic lateral sclerosis [J]. J Neuropathol Exp Neurol, 2007, 66(1): 10-16.
[32] Liu W, Yamashita T, Tian F, et al. Mitochondrial fusion and fission proteins expression dynamically change in a murine model of amyotrophic lateral sclerosis [J]. Curr Neurovasc Res, 2013, 10(3): 222-230.
[33] Palomo GM, Manfredi G. Exploring new pathways of neurodegeneration in ALS: the role of mitochondria quality control [J]. Brain Res, 2015, 1607: 36-46.
[34] Cozzolino M, Carrì MT. Mitochondrial dysfunction in ALS [J]. Prog Neurobiol, 2012, 97(2): 54-66.
[35] Meininger V. ALS, what new 144 years after Charcot? [J]. Arch Ital Biol, 2011, 149(1): 29-37.
[36] Farina C, Aloisi F, Meinl E. Astrocytes are active players in cerebral innate immunity [J]. Trends Immunol, 2007, 28(3): 138-145.
[37] Zürcher NR, Loggia ML, Lawson R, et al. Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: Assessed with [11 C]-PBR28 [J]. Neuroimage Clin, 2015, 7: 409-414.
[38] Wormser U, Mandrioli J, Vinceti M, et al. Reduced levels of alpha-1-antitrypsin in cerebrospinal fluid of amyotrophic lateral sclerosis patients: a novel approach for a potential treatment [J]. J Neuroinflammation, 2016, 13(1): 1-5.
[39] Lu CH, Allen K, Oei F, et al. Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis [J]. Neurol Neuroimmunol Neuroinflamm, 2016, 3(4): e244.
[40] Dahlke C, Saberi D, Ott B, et al. Inflammation and neuronal death in the motor cortex of the wobbler mouse, an ALS animal model [J]. J Neuroinflammation, 2015, 12(1): 1-11.
[41] May C, Nordhoff E, Casjens S, et al. Highly immunoreactive IgG antibodies directed against a set of twenty human proteins in the sera of patients with amyotrophic lateral sclerosis identified by protein array [J]. PLoS One, 2014, 9(2): e89596.
[42] Pagani MR, Gonzalez LE, Uchitel OD. Autoimmunity in amyotrophic lateral sclerosis: past and present [J]. Neurol Res Int, 2011, 2011: 497080.
[43] Nardo G, Trolese MC, de Vito G, et al. Immune response in peripheral axons delays disease progression in SOD1 G93A mice [J]. J Neuroinflammation, 2016, 13(1): 261.
[44] Orrell RW, Lane RJM, Ross M. A systematic review of antioxidant treatment for amyotrophic lateral sclerosis/motor neuron disease [J]. Amyotroph Lateral Scler, 2009, 9(4): 195-211.
[45] Glass JD, Hertzberg VS, Boulis NM, et al. Transplantation of spinal cord-derived neural stem cells for ALS: Analysis of phase 1 and 2 trials [J]. Neurology, 2016, 87(4): 392-400.

肌萎缩侧索硬化发病机制的研究进展

Advance in Pathogenesis of Amyotrophic Lateral Sclerosis (review)

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

Metrics

本文评价

推荐阅读 0

[1]	邵伟婷, 雷江华. 反应中断再定向干预孤独症谱系障碍儿童刻板语言的效果：Scoping综述[J]. 《中国康复理论与实践》, 2024, 30(1): 10-20.
[2]	王航宇, 葛可可, 范永红, 都丽露, 邹敏, 封磊. 基于ICD-11和ICF主动式音乐疗法改善认知障碍老年人认知功能的系统综述[J]. 《中国康复理论与实践》, 2024, 30(1): 36-43.
[3]	闻嘉宁, 金秋艳, 张琦, 李杰, 司琦. 认知参与型身体活动对发展儿童青少年执行功能的效果：基于ICF的系统综述[J]. 《中国康复理论与实践》, 2024, 30(1): 44-53.
[4]	葛可可, 范永红, 王航宇, 都丽露, 李长江, 邹敏. 失眠老年人正念干预健康效益的系统综述[J]. 《中国康复理论与实践》, 2024, 30(1): 54-60.
[5]	张婧雅, 邹敏, 孙宏伟, 孙昌隆, 朱峻同. 听障儿童青少年焦虑或抑郁情绪心理干预效果的系统综述[J]. 《中国康复理论与实践》, 2023, 29(9): 1004-1011.
[6]	王俊宇, 杨永, 袁逊, 谢婷, 庄洁. 高强度间歇训练对健康儿童青少年执行功能效果的系统综述[J]. 《中国康复理论与实践》, 2023, 29(9): 1012-1020.
[7]	魏晓微, 杨剑, 魏春艳. 特殊教育学校孤独症谱系障碍儿童参与适应性瑜伽活动的心理与行为效益的系统综述[J]. 《中国康复理论与实践》, 2023, 29(9): 1021-1028.
[8]	杨亚茹, 杨剑. 基于WHO-HPS架构学校身体活动相关健康服务及其健康效益：系统综述的系统综述[J]. 《中国康复理论与实践》, 2023, 29(9): 1040-1047.
[9]	史佳伟, 李凌宇, 杨浩杰, 王琴潞, 邹海欧. 预康复对全膝关节置换术后患者的有效性：系统综述的系统综述[J]. 《中国康复理论与实践》, 2023, 29(9): 1057-1064.
[10]	蒋长好, 黄辰, 高晓妍, 戴元富, 赵国明. 神经反馈训练对老年人认知功能效果的系统综述[J]. 《中国康复理论与实践》, 2023, 29(8): 903-909.
[11]	魏晓微, 杨剑, 魏春艳, 贺启令. 学校环境下适应性体育课程促进智力与发展性残疾儿童心理运动发展的系统综述[J]. 《中国康复理论与实践》, 2023, 29(8): 910-918.
[12]	张园, 杨剑. 基于世界卫生组织健康促进学校架构的学校健康服务及效果：Scoping综述[J]. 《中国康复理论与实践》, 2023, 29(7): 791-799.
[13]	王少璞, 陈钢. 基于世界卫生组织健康促进学校架构的心理行为健康服务及其健康效益：系统综述的系统综述[J]. 《中国康复理论与实践》, 2023, 29(7): 800-807.
[14]	蒋长好, 高晓妍. 短时身体活动对儿童认知功能影响的系统综述[J]. 《中国康复理论与实践》, 2023, 29(6): 667-672.
[15]	袁媛, 杨剑. 社区老年人身体活动融合慢性病管理的健康效益：Scoping综述[J]. 《中国康复理论与实践》, 2023, 29(5): 541-550.